NDA 050475 · Bausch
Gris-Peg
Griseofulvin, Ultramicrosize · Oral
Last checked: Nov 19, 2026Latest source record: Dec 28, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1975
Apr 16, 1975
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 16, 1975 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
- GRIS-PEG · GRISEOFULVIN, ULTRAMICROSIZE 125MG · TABLET, ORAL · Prescription · TE AB
- GRIS-PEG · GRISEOFULVIN, ULTRAMICROSIZE 250MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Griseofulvin" as an intervention, any sponsor and status, largest first.
- Terbinafine Compared to Griseofulvin in Children With Tinea CapitisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00117754 · 720 participants · Start Jul 2004
Drug: Terbinafine hydrochloride · For: Tinea Capitis
Sites: East Hanover, New Jersey
- Terbinafine Compared to Griseofulvin in Children With Tinea CapitisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00117767 · 720 participants · Start Jun 2004 · Primary completion Mar 2006
Drug: Terbinafine hydrochloride (HCl); Griseofulvin · For: Tinea Capitis
Sites: East Hanover, New Jersey
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01518166 · 70 participants · Start May 2006 · Primary completion Apr 2007
Drug: liraglutide; placebo and 4 more · For: Diabetes; Healthy
Sites: Uppsala, Sweden
- A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting ConditionsCompleted
Actavis Inc.Industry
NCT00864071 · 50 participants · Start Nov 2005 · Primary completion Nov 2005
Drug: Griseofulvin 125 mg/5 mL Suspension, single dose; Grifulvin V® 125 mg/5 mL Suspension, single dose · For: Healthy
Sites: Toronto, Canada
Chen, Catherine, M.D.Academic, hospital or other
NCT00127868 · 47 participants · Start Mar 2005 · Primary completion Apr 2008
Drug: oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo · For: Tinea Capitis
Sites: Norfolk, Virginia
- A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting ConditionsCompleted
Actavis Inc.Industry
NCT00863863 · 40 participants · Start Jan 2006 · Primary completion Jan 2006
Drug: Griseofulvin 125 mg/5 mL Suspension, single dose; Grifulvin V® 125 mg/5 mL Suspension, single dose · For: Healthy
Sites: Toronto, Canada
GlaxoSmithKlineGSK (GSK)
NCT04318535 · 36 participants · Start Jan 13, 2020 · Primary completion Jan 13, 2020
Drug: Griseofulvin 500 mg; Griseofulvin 250 mg and 1 more · For: Antifungal Agents
Sites: Navi Mumbai, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.
Mergenhagen KA, Wattengel BA, Skelly MK, et al. · Antimicrob Agents Chemother 2020 · Research Support, U.S. Gov't, Non-P.H.S., Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2008 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2011 · Systematic Review
- Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis.
Tey HL, Tan AS, Chan YC · J Am Acad Dermatol 2011 · Meta-Analysis
- A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group.
Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. · Br J Dermatol 1994 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Oral treatments for fungal infections of the skin of the foot.
Bell-Syer SE, Hart R, Crawford F, et al. · Cochrane Database Syst Rev 2002 · Systematic Review
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.